Radioimmunotoxins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 4831122
SERIAL NO

06817398

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Radioimmunotoxins consisting of a monoclonal antibody covalently coupled to a toxin and a radionuclide. The compositions retain high binding specificity and cytotoxic activity and are useful in treating cancer and in bone marrow transplantation. The antibody component determines the selectivity. The toxin component kills the targeted cells. The radionuclide component also kills, but by a different mechanism, thus ensuring the eradication of all tumor cells. The radionuclide also allows the radioimmunotoxin to be tracked in vivo which enables the determination of its distribution throughout the body. Also, the pharmacokinetics of injected radioimmunotoxin can be determined allowing for more exact dose quantitation and administration.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
REGENTS OF THE UNIVERSITY OF MINNESOTA THE450 UNIVERSITY GATEWAY 200 OAK STREET SE UNIVERSITY OF MINNESOTA MINNEAPOLIS MN 55455

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Buchsbaum, Donald J Minnetonka, MN 29 355
Vallera, Daniel A Minneapolis, MN 20 190

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation